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Of note is that senescent T-cells do not express CD28,
but that, on the other hand, not all CD28− T-cells are
senescent.
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The impact of antiretroviral
therapy on HIVAN
To the Editor: We read with interest the article by
Wei et al [1] on the association between anigotensin-
converting enzyme inhibition (ACE-I) and outcomes
among patients with human immunodeficiency virus–
associated nephropathy (HIVAN). We are concerned
about the inherent limitations in making concrete con-
clusions from observational data and would caution
nephrologists against relying too heavily on ACEI, while
de-emphasizing the role of antiretroviral therapy (ARV)
in the treatment of HIVAN. The authors show that fos-
inopril, not ARV, is an important predictor of mortality.
With the introduction of highly active antiretroviral ther-
apy (HAART), the survival benefit from ARV therapy is
indisputable. Failure to show such a benefit raises impor-
tant questions about the data; specifically, what classes
of ARV were available during the course of this study.
In the absence of more information in this regard, it is
conceivable that the benefits of ACE-I, which decreased
the risk of death 100-fold, may be overstated.
The cohort was recruited between 1993–1997 before
the availability of HAART, and the current work rep-
resents long-term follow-up of the original survivors.
Only 16 patients were followed for more than one year,
minimally overlapping the contemporary era in which
HAART has so significantly improved survival. Most of
these patients were treated with ACE-I and were orig-
inally coded as not taking ARV. Because most of the
deaths occurred within the first year of enrollment, it
would not be fair to ascribe long-term benefits of sur-
vivors to ACE-I if, in fact, survivors had access to potent
ARV, such as HAART, years after they were coded as
not having been treated at baseline. Another concern is
the observation that the cohort includes 11 patients who
survived but were followed for less than one year. All 11
of these patients were taking ARV. Said another way, sur-
vivors not taking ARV were followed for 1200 days, while
survivors taking ARV were followed for only 385 days.
There seems to be considerable nonrandom loss to
follow-up in the ARV group, which by itself would skew
the data to more favorable outcomes for ACE-I. Bias
could also be introduced by factors not included in this
analysis, such as perceptions about patient compliance,
which could influence the decision to begin antiretrovi-
ral therapy or ACE-I, HIV RNA levels, and how CD4
count and HIV RNA levels change over time with ARV.
Finally, nonrandom misclassification bias likely impacted
the significance of ARV on outcomes. The definition of
ARV exposure is ≥30 consecutive days. This is not suffi-
cient exposure to derive any meaningful benefit from the
drugs, yet patients with minimal exposure could easily
have been labeled as having been treated.
Therefore, for these reasons, we do not believe these
data can assess the impact of ARV on renal outcomes
among patients with HIVAN. Given prior reports which
suggest that increasing CD4 lymphocyte counts and non-
detectable HIV RNA levels are associated with better
renal outcomes [2, 3], and the trend toward greater use
of antiretroviral medications in the group receiving fos-
inopril, we believe that the real question not addressed
by these data becomes “Does disrupting the renin-
angiotensin system affect the progression of HIVAN
among patients with effective suppression of viral
replication?”
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